Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | oyce Liu, William Thomas Barry, Michael J. Birrer, Jung-min Lee, Ronald J. Buckanovich, Gini F. Fleming, Bj Rimel, Mary K. Buss, Sreenivasa R. Nattam, Jean Hurteau, Weixiu Luo, Philippa Quy, Elizabeth Obermayer, Christin Whalen, Hang Lee, Eric P. Winer, Elise C. Kohn, S. Percy Ivy, Ursula Matulonis | ||||||||||||
Title | A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer. | ||||||||||||
|
|||||||||||||
URL | http://meetinglibrary.asco.org/content/130933-144 | ||||||||||||
Abstract Text | suppl; abstr LBA5500 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|